** Shares of Argenica Therapeutics AGN.AX rise as much as 2.1% to A$0.735 to hit highest level since June 11; last up 0.7%
** Biotechnology co gets federal government funding up to A$1.5 million ($972,600.00) to advance later stage clinical trial of ARG-007 being developed to treat stroke patients
** Stock up ~15% this year, including the day's move
($1 = 1.5423 Australian dollars)
(Reporting by John Biju in Bengaluru)
((John.Biju@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.